Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain
IMPORTANCE OF THE FIELD: Despite proven analgesic efficacy, opioid use is associated with frequently dose-limiting bowel dysfunction that seriously impacts patients' quality of life (QoL). Agents used at present to manage opioid-induced constipation do not address the underlying opioid receptor...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2010
|
| In: |
Expert opinion on pharmacotherapy
Year: 2010, Volume: 11, Issue: 2, Pages: 297-310 |
| ISSN: | 1744-7666 |
| DOI: | 10.1517/14656560903483222 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1517/14656560903483222
|
| Author Notes: | Katri Elina Clemens, Gerd Mikus |
| Summary: | IMPORTANCE OF THE FIELD: Despite proven analgesic efficacy, opioid use is associated with frequently dose-limiting bowel dysfunction that seriously impacts patients' quality of life (QoL). Agents used at present to manage opioid-induced constipation do not address the underlying opioid receptor-mediated cause of bowel dysfunction and are often ineffective. There is, therefore, a significant need for more effective treatment options. The combination of the strong opioid oxycodone and the opioid antagonist naloxone has the potential to prevent opioid-induced bowel dysfunction (OIBD) while maintaining analgesic efficacy. - OBJECTIVE: To review the safety and efficacy of oral prolonged-release (PR) oxycodone/naloxone in the treatment of patients experiencing chronic pain. - AREAS COVERED IN THIS REVIEW: A MEDLINE search was done (January 2002 - July 2009) for available literature for prolonged release oxycodone and naloxone in different patient groups. Results were limited to English-language and clinical trials. Data were also obtained from congress materials. WHAT KNOWLEDGE THE READER WILL GAIN: Unmet needs of opioid pain treatment in terms of OIBD, reduced QoL and low treatment compliance, leading to reduced efficacy. A data overview demonstrates the efficacy and tolerability of PR oxycodone/naloxone in the management of severe chronic pain without the burden of severe gastrointestinal adverse events. The combined formulation of a highly effective opioid and an antagonist that acts locally to reduce gastrointestinal side effects is expected to simplify pain management. - TAKE HOME MESSAGE: The combination of PR oxycodone/naloxone offers the potential of maintaining normal bowel function in patients requiring opioid therapy--it is a strong analgesic that is well tolerated. |
|---|---|
| Item Description: | Published online: 23 December 2009 Gesehen am 05.05.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1744-7666 |
| DOI: | 10.1517/14656560903483222 |